Jazz Pharmaceuticals (JAZZ) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a ...

2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its ...

Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ ...

Jazz Pharmaceuticals has acquired Chimerix Inc. for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.

About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.

Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment. Jazz Pharmaceuticals markets multiple ...

Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Amphastar Pharmaceuticals (AMPH – Research Report) today and set ...

Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment. Jazz Pharmaceuticals markets multiple ...